Analytical Data
-
Gene name
PODN
- Application
-
Alternative Names
PCAN; SLRR5A
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q7Z5L7
-
Expression Region
Gly20~Arg613
-
Molecular Weight
80kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PODN (Peroxiredoxin-NADPH Oxidase) is a type of recombinant protein that plays a crucial role in cellular redox signaling and antioxidant defense. Recent research has highlighted the significance of PODN in various biological processes, including inflammation, cell proliferation, and apoptosis. This protein is part of the peroxiredoxin family, which is known for its ability to reduce reactive oxygen species (ROS), thereby protecting cells from oxidative stress. The increased understanding of PODN's function has sparked interest among scientists in exploring its therapeutic potential, particularly in the context of diseases characterized by oxidative stress and inflammation, such as cancer and neurodegenerative disorders. Additionally, advances in recombinant DNA technology have facilitated the production of PODN in various host organisms, including bacteria and yeasts, allowing for detailed structural and functional analyses. These advancements have led to the investigation of PODN's application in biomedicine, including its role as a biomarker for disease diagnosis and a target for drug development. Understanding the mechanisms by which PODN operates within cells could pave the way for novel therapeutic strategies aimed at modulating its activity to combat oxidative stress-related diseases, thereby enhancing health outcomes and improving therapeutic interventions. Overall, the study of PODN as a recombinant protein presents a promising avenue for scientific inquiry, with potential implications for a wide range of clinical applications.
